These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16800349)

  • 1. Exjade (ICL 670): A new oral iron chelator.
    Agarwal MB
    J Assoc Physicians India; 2006 Mar; 54():214-7. PubMed ID: 16800349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferasirox: the new oral iron chelator.
    Dubey AP; Sudha S; Parakh A
    Indian Pediatr; 2007 Aug; 44(8):603-7. PubMed ID: 17827637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron-chelating therapy with the new oral agent ICL670 (Exjade).
    Cappellini MD
    Best Pract Res Clin Haematol; 2005 Jun; 18(2):289-98. PubMed ID: 15737891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox for transfusion-related iron overload: a clinical review.
    Lindsey WT; Olin BR
    Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE; Hagemann TM
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.
    Galanello R; Piga A; Alberti D; Rouan MC; Bigler H; Séchaud R
    J Clin Pharmacol; 2003 Jun; 43(6):565-72. PubMed ID: 12817519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Galanello R
    Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
    Taher AT; Temraz S; Cappellini MD
    Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferasirox (Exjade): a new iron chelator.
    Med Lett Drugs Ther; 2006 Apr; 48(1233):35-6. PubMed ID: 16625144
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
    Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
    Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferasirox: An effective once-daily orally active iron chelator.
    Porter JB
    Drugs Today (Barc); 2006 Oct; 42(10):623-37. PubMed ID: 17136223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD; Taher A
    Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of deferasirox.
    Cappellini MD
    Blood Rev; 2008 Dec; 22 Suppl 2():S35-41. PubMed ID: 19059055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
    Nick H; Allegrini PR; Fozard L; Junker U; Rojkjaer L; Salie R; Niederkofler V; O'Reilly T
    Exp Biol Med (Maywood); 2009 May; 234(5):492-503. PubMed ID: 19234060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
    Imran F; Phatak P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):297-304. PubMed ID: 19670988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
    Unal S; Hazirolan T; Eldem G; Gumruk F
    Pediatr Hematol Oncol; 2011 Apr; 28(3):217-21. PubMed ID: 21083355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
    Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
    Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.